Orexo's patent win for ZUBSOLV® appealed
UPPSALA, Sweden, July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc.,...
- Supported exchanges /
- ST /
- ORX.ST
Orexo AB (ORX ST) stock market data APIs
kr9.34
-0.21(-2.2%)
as of November 22, 2024
Price chart is built with Anychart
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB Financial Data Overview
| 9.75 | |
| 9.34 | |
| - | |
| 9.5 | |
| 8.93 | |
| 9.18-23.3 | |
| 324 M | |
| 34 450 K | |
| 596 M | |
| -1.21 | |
| 0.599 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'ORX',
Type:
'Common Stock',
Name:
'Orexo AB',
Exchange:
'ST',
CurrencyCode:
'SEK',
CurrencyName:
'Swedish krone',
CurrencySymbol:
'kr',
CountryName:
'Sweden',
CountryISO:
'SE',
OpenFigi:
NULL,
ISIN:
'SE0000736415',
CIK:
NULL,
EmployerIdNumber:
'',
FiscalYearEnd:
'December',
IPODate:
'2005-11-09',
InternationalDomestic:
'International',
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - Specialty & Generic',
}
Orexo AB Fundamental Data is available in our Financial Data APIs
- Net Revenue 596 M
- EBITDA 67 800 K
- Earnings Per Share -3.05
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Orexo AB Earnings via APIs
- Latest Release 2024-10-24
- EPS/Forecast -0.82
Get Orexo AB End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Orexo AB latest news via APIs
Orexo Q2 2023 Interim Report
UPPSALA, Sweden, July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights › Total net revenues of SEK 157.7 m (147.8) › EBITDA of SEK 5....
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
